ORIC Pharmaceuticals Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 119

Employees

  • Stock Symbol
  • ORIC

Stock Symbol

  • Share Price
  • $7.35
  • (As of Friday Closing)

ORIC Pharmaceuticals General Information

Description

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 240 East Grand Avenue
  • 2nd Floor
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 240 East Grand Avenue
  • 2nd Floor
  • South San Francisco, CA 94080
  • United States
+1 (650)

ORIC Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ORIC Pharmaceuticals Stock Performance

As of 20-Nov-2026, ORIC Pharmaceuticals’s stock price is $7.35. Its current market cap is $765M with 104M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.35 $7.70 $7.23 - $14.68 $765M 104M 1.58M -$1.47

ORIC Pharmaceuticals Financials Summary

As of 30-Sep-2026, ORIC Pharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,134,765 512,805 300,227 277,309
Revenue 0 0 0 0
EBITDA (154,707) (128,248) (126,740) (99,665)
Net Income (155,840) (129,468) (127,847) (100,697)
Total Assets 366,886 408,890 274,142 252,007
Total Debt 3,352 3,330 3,183 2,752
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ORIC Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ORIC Pharmaceuticals‘s full profile, request access.

Request a free trial

ORIC Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore ORIC Pharmaceuticals‘s full profile, request access.

Request a free trial

ORIC Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to count
Drug Discovery
South San Francisco, CA
119 As of 2026

San Diego, CA
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ORIC Pharmaceuticals Competitors (85)

One of ORIC Pharmaceuticals’s 85 competitors is ImmunityBio, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ImmunityBio Formerly VC-backed San Diego, CA
Mustang Bio Formerly VC-backed Waltham, MA
Evotec Formerly PE-Backed Hamburg, Germany
Agios Pharmaceuticals Formerly VC-backed Cambridge, MA
Celldex Formerly VC-backed Hampton, NJ
You’re viewing 5 of 85 competitors. Get the full list »

ORIC Pharmaceuticals Patents

ORIC Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026236194-A1 Treatment of breast cancer Pending 06-May-2025
WO-2026217890-A1 Compounds for use in the treatment of cancer Pending 11-Apr-2025
WO-2026217431-A1 Treatment of lung cancer Pending 07-Apr-2025
WO-2026207203-A1 Treatment of colorectal cancer Pending 27-Mar-2025
WO-2026207077-A1 Pharmaceutical compositions comprising an inhibitor of egfr Pending 26-Mar-2025 A61K9/2054
To view ORIC Pharmaceuticals’s complete patent history, request access »

ORIC Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ORIC Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ORIC Pharmaceuticals‘s full profile, request access.

Request a free trial

ORIC Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 08, 2026

37.37 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view ORIC Pharmaceuticals’s complete esg history, request access »

ORIC Pharmaceuticals FAQs

  • When was ORIC Pharmaceuticals founded?

    ORIC Pharmaceuticals was founded in 2014.

  • Where is ORIC Pharmaceuticals headquartered?

    ORIC Pharmaceuticals is headquartered in South San Francisco, CA.

  • What is the size of ORIC Pharmaceuticals?

    ORIC Pharmaceuticals has 119 total employees.

  • What industry is ORIC Pharmaceuticals in?

    ORIC Pharmaceuticals’s primary industry is Drug Discovery.

  • Is ORIC Pharmaceuticals a private or public company?

    ORIC Pharmaceuticals is a Public company.

  • What is ORIC Pharmaceuticals’s stock symbol?

    The ticker symbol for ORIC Pharmaceuticals is ORIC.

  • What is the current stock price of ORIC Pharmaceuticals?

    As of 20-Nov-2026 the stock price of ORIC Pharmaceuticals is $7.35.

  • What is the current market cap of ORIC Pharmaceuticals?

    The current market capitalization of ORIC Pharmaceuticals is $765M.

  • Who are ORIC Pharmaceuticals’s competitors?

    ImmunityBio, Mustang Bio, Evotec, Agios Pharmaceuticals, and Celldex are some of the 85 competitors of ORIC Pharmaceuticals.

  • What is ORIC Pharmaceuticals’s annual earnings per share (EPS)?

    ORIC Pharmaceuticals’s EPS for 12 months was -$1.47.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process